Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Decreases By 97.9%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 150,000 shares, a decrease of 97.9% from the December 15th total of 7,300,000 shares. Currently, 16.5% of the shares of the company are short sold. Based on an average daily volume of 906,000 shares, the days-to-cover ratio is currently 0.2 days.

CERo Therapeutics Stock Down 17.3 %

CERo Therapeutics stock traded down $0.57 during mid-day trading on Tuesday, reaching $2.72. 229,504 shares of the stock traded hands, compared to its average volume of 1,700,875. CERo Therapeutics has a 12-month low of $2.67 and a 12-month high of $1,280.00. The business’s 50-day moving average is $11.81 and its 200-day moving average is $13.07.

Insider Activity

In related news, major shareholder Bioventures Opportunities G. Yk sold 12,368 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.00, for a total value of $148,416.00. Following the sale, the insider now owns 213,839 shares in the company, valued at approximately $2,566,068. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 64,300 shares of company stock valued at $529,409 over the last ninety days. 18.00% of the stock is currently owned by corporate insiders.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.